Previous 10 | Next 10 |
2024-02-09 22:17:09 ET Summary David Abrams' 13F portfolio value increased from $3.03B to $3.22B this quarter. Meta Platforms and Teva Pharmaceutical saw stake decreases in Abrams' portfolio. Abrams kept steady positions in Lithia Motors, Asbury Automotive, Alphabet Inc., and ...
2024-02-08 09:10:29 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to i...
2024-01-31 11:50:06 ET Teva Pharmaceutical Industries Limited (TEVA) Q4 2023 Earnings Conference Call January 31, 2024 8:00 am ET Company Participants Richard Francis - President, Chief Executive Officer Eric Hughes - Executive Vice President, Global R&D, Chief M...
2024-01-31 11:34:01 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript) Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating) Teva Pharmaceutical Industries Limi...
2024-01-31 09:17:00 ET U.S. stock index futures on Wednesday were mixed , with the tech-heavy Nasdaq 100 futures ( NDX:IND ) index weighed down by a post-earnings fall in Alphabet ( GOOG ) ( GOOGL ) and AMD ( AMD ). Here are some stocks to watch on Wednesday: ... ...
2024-01-31 07:04:24 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript) Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating) Teva Pharmaceutical Industries Limi...
2023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO ® - exceeding $1.2 billion in annual revenues, up 28% from 2022; strong growth expected to continue in 2024 with expected revenues of ~$1.5 billion; AJOVY ® - globa...
2024-01-31 06:25:57 ET Teva ( NYSE: TEVA ) plans to divest its active-pharmaceutical ingredient (API) business as part of its Pivot to Growth strategy to focus on its core business strengths.... Read the full article on Seeking Alpha For further details see: Teva...
Landmark Bancorp Inc. (LARK) is expected to report for Q4 2023 BrightView Holdings Inc. (BV) is expected to report $0.02 for Q1 2024 Roper Technologies Inc. (ROP) is expected to report $4.33 for Q4 2023 Columbus McKinnon Corporation (CMCO) is expected to report $0.69 for Q3 2024 W...
The intended divestiture is expected to play an important role in Teva's “Pivot to Growth” strategy as it will allow Teva to focus on its core business strengths and on capital allocation towards growth engines and innovation Such intended divestiture of Teva’s API busine...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...